A Case Report Of Linezolid (Lzd) Induced Complete Myelosuppression
Linezolid (Lzd) Induced Complete Myelosuppression
DOI:
https://doi.org/10.70284/njirm.v8i1.1184Keywords:
Linezolid (Lzd), Myelosuppression, SepticaemiaAbstract
Linezolid (Lzd) is an oxazolidinone group of antibiotic used for the treatment of serious infections caused by Gram-positive bacteria that cause disease, including streptococci, vancomycin-resistant enterococci (VRE), and methicillin-resistant Staphylococcus aureus (MRSA). Lzd is associated with adverse haematological effects particularly thrombocytopenia. But pancytopenia and complete myelosuppression is a rare adverse reaction. This is a case report of a 50-year male patient diagnosed as Lower limb cellulitis with septicaemia and was started on Tab. Lzd 600mg BD along with other drugs and supportive treatments. He developed pancytopenia after 4 days of treatment. Lzd was stopped. Patient’s blood count improved significantly after 7 days of drug withdrawal. Hence physicians need to be aware of this rare but serious side effect of Lzd and the importance of routine haematological monitoring to decrease the morbidity and mortality. [Vedang T NJIRM 2017; 8(1):126-128]
References
2. Draghi DC, Sheehan DF, Hogan P, et al. Current antimicrobial resistance profiles among methicillin-resistant Staphylococcus aureus encountered in the outpatient setting. Diagn Microbial Infect Dis. 2006; 55:129-133.
3. Ahmad K. MRSA becomes growing problem in US emergency departments. Lancet Infect Dis. 2006; 6:621.
4. Katzung BG and Trevor AJ, Tetracyclines, Macrolides, Clindamycin, Chloramphenicol, Streptogramins, &Oxazolidinones, Basic& Clinical Pharmacology,13th edition, New Delhi: Mc Graw Hill Education LANGE,2015, 1072.
5. Sweatman SC, Antibacterials, Martindale the Complete Drug Reference,36thedition, China: Pharmaceutical Press,2009, 293,294, 837.
6. B. Natsumoto. K. Yokota, et al. Risk factors for Lzd-associated thrombocytopenia in adult patients.
7. Physician desk reference. 55th ed. Montvale, NJ: Medical Economics Company, 2001:2656–60.
8. Green, S. L., J. C. Maddox, and E. D. Huttenbach. Lzd and reversible myelosuppression. 2001 JAMA 285:1291.
9. Garg R, Mishra AK, et al. Linezolid induced pancytopenia in a patient of extensively drug-resistant pulmonary tuberculosis: An unusual outcome. J Assoc Chest Physicians 2016; 4: 21-3.
10. P. Cossu, M. Musu, P. Lzd-induced thrombocytopenia in impaired renal function: is it time for a dose adjustment? A case report and review of literature, Mura European Journal of Clinical Pharmacology, 2013, Page 1.
